Physician profile
Sarah Bertzyk
NPI 1316652373
$5,468.00
in general payments reported to CMS, 2019-2025
15 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,493 · 2024: $1,745 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,214 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,214.02 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,439.72 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,311.68 | 2023-2025 | |
| Gilead Sciences, INC. | $663.58 | 2023-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $443.83 | 2024-2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $410.33 | 2023-2025 | Entyvio |
| Genzyme Corporation | $401.59 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $297.53 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $191.63 | 2024 | |
| Ardelyx, INC. | $105.91 | 2023-2024 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $55.27 | 2025 | Iqirvo |
| Qol Medical, LLC | $42.71 | 2024 | Sucraid |
| Pfizer INC. | $41.66 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $24.05 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $20.44 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.07 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bertzyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.